Anti-Viral Drugs for Human Adenoviruses
by
Mary Miu Yee Waye *
and Chor Wing Sing
Mary Miu Yee Waye * and Chor Wing Sing
School of Biomedical Sciences, Croucher Laboratory for Human Genomics, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2010, 3(10), 3343-3354; https://doi.org/10.3390/ph3103343
Received: 2 September 2010 / Revised: 23 October 2010 / Accepted: 25 October 2010 / Published: 25 October 2010
(This article belongs to the Special Issue Antivirals)
There are many stages in the development of a new drug for viral infection and such processes are even further complicated for adenovirus by the fact that there are at least 51 serotypes, forming six distinct groups (A–F), with different degree of infectivity. This review attempts to address the importance of developing pharmaceuticals for adenovirus and also review recent development in drug discovery for adenovirus, including newer strategies such as microRNA approaches. Different drug screening strategies will also be discussed.
View Full-Text
Keywords:
adenovirus; pharmaceuticals; microRNA
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License
MDPI and ACS Style
Waye, M.M.Y.; Sing, C.W. Anti-Viral Drugs for Human Adenoviruses. Pharmaceuticals 2010, 3, 3343-3354.
Show more citation formats
